Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WELLCOME STUDYING REVERSE TRANSCRIPTASE IN SPACE; DEC. 18 SHUTTLE FLIGHT

Executive Summary

WELLCOME STUDYING REVERSE TRANSCRIPTASE IN SPACE; DEC. 18 SHUTTLE FLIGHT, scheduled for launch from Cape Canaveral, Florida will include a Wellcome Research Labs project to evaluate the three-dimensional structure of the enzyme. Burroughs Wellcome's Retrovir (AZT) is effective in treating AIDS because of its inhibitor effect on reverse transcriptase. The reverse transcriptase work will be one of 120 protein crystal growth experiments to be conducted on board the space shuttle Columbia. Previous space flight experiments have shown that crystals grown in a gravity-free environment are larger and higher in quality than those grown in Earth-bound laboratories. Upon the shuttle's return, X-ray crystallography will be used to determine the three-dimensional structure of the compound under study. The crystal growth experiments on the Columbia will be the sixth such studies conducted on space shuttle flights. The NASA project is being directed by Charles Bugg, PhD, director of the Center for Macromolecular Crystallography and a senior scientist at the University of Alabama at Birmingham. Initial evaluation of the experiments from the Columbia will be conducted at UAB upon the return of the space shuttle. In addition to reverse transcriptase, other crystals will be grown on the shuttle flight, including aldose reductase, which is being studied by BioCryst and the University of Alabama for its role in diabetic complications. Merck and ICI have been developing an aldose reductase inhibitor (ponalrestat) for several years in a long-term clinical development project. Other compounds under evaluation include phospholipase A-2, which is is being evaluated by Upjohn for its part in the function of the cell membrane as a means of developing new drugs for pain and inflammation, and porcine elastase, which is being studied by Vertex Pharmaceuticals for its association with emphysema. BioCryst is an R&D start-up formed to develop commercial applications of X-ray crystallography based in Birmingham, Ala. Vertex is a drug design R&D firm based in Cambridge, Mass. Pharmaceutical products involved in the crystal growing experiments include DuPont's anti-rejection drug cyclosporin A, SmithKline & French's antibiotic aridicin aglycone, Schering-Plough's gamma interferon, and Lilly's human growth hormone. Also on board are projects involving agricultural diseases and treatments. While similar protein crystal growth experiments have been conducted on six previous shuttle flights, the Dec. 18 mission is scheduled to remain in space for at least nine days, compared to less than three days for earlier flights. As a result, scientists will be able to grow crystals at lower temperatures, which is expected to improve results.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest News
See All
UsernamePublicRestriction

Register

PS016675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel